Abbott Laboratories (ABT) Pacemakers Get FDA Approval
The Tendril MRI pacing lead and the Assurity MRI pacemaker have been approved by the U.S. Food and Drug Administration.
Author Archive - Market Exclusive
Advair, Armonair From Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets FDA Approval
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has announced the approval of AirDuo RespiClick and ArmonAir RespiClick by the U.S. Food and Drug Administration.
The European Medicines Agency (EMA) Recommends KEYTRUDA From Merck & Co., Inc. (MRK)
The European Commission has approved KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy from Merck & Co., Inc. (NYSE:MRK).
Pharmaceutical Executives From Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ) Met Trump
United States President Donald Trump is urging US drugmakers to consider manufacturing more of their drugs in the United States, thinking that higher cost manufacturing at the...
Catabasis Pharmaceuticals Inc (CATB): What’s Next?
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is the latest biotechnology company to fall foul of some disappointing data in the space.
Calithera Biosciences Inc (CALA): What You Need To Know
Calithera Biosciences Inc (NASDAQ:CALA) is an early week runner, with the company currently trading at around a 46% premium to its Monday morning open.
Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)
Trials of rival drugs from AstraZeneca PLC (ADR) (NYSE:AZN) and TESARO Inc (NASDAQ:TSRO) will determine the adoption of the PARP inhibitor, Rubraca from Clovis Oncology Inc (NASDAQ...
A U.S Court Will Hear Nothing Of Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Claims Of Patent Infringement
A U.S. court has rejected four claims of patent infringement from Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Athersys, Inc. (ATHX) Down, Maybe An Opportunity?
At the end of last week, Athersys, Inc. (NASDAQ:ATHX) announced a public offering that will see it distribute just shy of 20 million shares at $1.01 a share.
AstraZeneca PLC (ADR) (AZN) Wins A Six Months Paediatric Exclusivity Approval Of Its Symbicort
The US Food and Drug Administration (FDA) has confirmed that Symbicort (budesonide/formoterol) Inhalation Aerosol is worth being granted paediatric exclusivity.
Merck & Co., Inc. (MRK) Is Among Many Drugmakers Being Criticized For Price Hikes
Merck & Co., Inc. (NYSE:MRK) is one of the pharma industry titans that are currently on the receiving end as a result of exaggerated drug price hikes.
Celgene Corporation (CELG) To Acquire Autoimmune Firm Delinia For $775 Million
Five months ago, Delinia was just a fledgling autoimmune startup with just four full-time staff.
Tenax Therapeutics Inc (TENX) Might Be A Discount Opportunity Ahead Of January Release
Tenax Therapeutics Inc (NASDAQ:TENX) is a North Carolina-based biotechnology company focusing on the development of treatments for what is called the critical care market - a...
Beigene Ltd (ADR) (BGNE): Here’s Our Take
Beigene Ltd (ADR) (NASDAQ:BGNE) had a pretty tough time throughout the latter half of November and early to mid December.
Aviragen Therapeutics Inc (AVIR) Could Start To Move Near Term
It seems only recently that the company wrapped up the completion of Phase 2a clinical trials for its respiratory syncytial virus (RSV) drug BTA585, but Aviragen Therapeutics ...
Celgene Corporation (CELG) Eyes Expansion In 2017
Celgene Corporation (NASDAQ:CELG) announced today its 2017 GAAP earnings per share of $5.85–$6.21.
Cabiralizumab From Five Prime Therapeutics Inc (FPRX) Obtains Orphan Designation
The European Commission has certified orphan designation for cabiralizumab.
FDA Approves Trulance From Synergy Pharmaceuticals Inc (SGYP) To Battle With Allergan PLC (AGN) Linzess
The chronic idiopathic constipation (CIC) market has a new entrant. This was occasioned by the FDA’s approval of Trulance from Synergy Pharmaceuticals Inc (NASDAQ:SGYP).
Aethlon Medical Inc. (AEMD) Readies CTE Blood Diagnostic Trial As Super Bowl LI Approaches
Super Bowl season is upon us, and every year more and more focus this time of year gets placed on a brain disease known as chronic traumatic encephalopathy (CTE).
Bristol-Myers Squibb Co (BMY) To Share In Sales Of Merck & Co., Inc. (MRK) Keytruda Following Litigation Settlement
Merck & Co., Inc. (NYSE:MRK) has agreed to share a portion of Keytruda sales with Bristol-Myers Squibb Co (NYSE:BMY) and Ono Pharmaceutical Co., Ltd.
Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?
Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE:LLY) severe competition...
Ironwood Pharmaceuticals, Inc. (IRWD) Has A Near Term Catalyst To Watch
Ironwood Pharmaceuticals, Inc.
Losses and Gains For Gilead Sciences, Inc. (GILD) Under President Trump Expected
There are almost too many speculations of changes to come in Washington, D.C.
Here’s What A Concert Pharmaceuticals Inc (CNCE) Data Win Might Mean For The Company
The final six months 2015, and pretty much the entirety of 2016, proved a tough period for the majority of biotechnology companies.
Here’s What’s Important About The Latest AbbVie Inc (ABBV) Approval
AbbVie Inc (NYSE:ABBV) just announced that it has picked up approval for one of its lead development candidates, but the company has failed to really move on the announcement.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Secures FDA Approval For Vantreal ER
Patients with severe pain that demands long-term, around-the-clock treatment now have a new medication to try.
Agenus Inc (AGEN) Incorporates NCI In Evaluation Of Prophage-Keytruda Combo
Having agreed on a collaborative deal, Agenus Inc (NASDAQ:AGEN) and National Cancer Institute (NCI) will work together in evaluating Agenus’ personalized autologous vaccine ...
Here’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) Deal
Eli Lilly and Co (NYSE:LLY) just announced that it is set to acquire junior biotech CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) in a deal worth up to $960 million.
Merck & Co., Inc. (MRK) And Palantir Technologies Inc Agree On Cancer Data Analysis Pact
Palantir Technologies Inc and Merck & Co., Inc.
ACCURATE Study Confirms Superiority Of Abbott Laboratories (ABT) Dorsal Root Ganglion (DRG) Stimulation
Abbott Laboratories (NYSE:ABT)'s dorsal root ganglion (DRG) stimulation therapy has advantages over traditional spinal cord stimulation (SCS) in the treatment of patients suffering...
Alcobra Ltd (ADHD): Here’s Our Take
Alcobra Ltd (NASDAQ:ADHD) lost more than 50% of its market capitalization during Tuesday’s session, and ahead of the market open on Wednesday, is down a further few percentage...
Here Are Two Market Moving Biotech Catalysts To Watch This Week
The biotechnology sector is in full swing for the New Year, and while the JP Morgan conference is now in the rearview mirror, there are still plenty of potential catalysts set...
Synergy Pharmaceuticals Inc (SGYP): A Top January Pick Ahead Of PDUFA
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has gradually picked up strength over the last six months or so, as the company creeps towards its PDUFA date for Plecanatide.
Here’s What Happens Now At Nivalis Therapeutics Inc (NVLS)
Nivalis Therapeutics Inc (NASDAQ:NVLS) is one of the first spectacular failure stories of 2017.
The Three Most Important Questions For TESARO Inc (TSRO) Shareholders Right Now
TESARO Inc (NASDAQ:TSRO) took a bit of a hit early Thursday morning, as the FDA announced it had issued a complete response letter (CRL) to the company relating to its latest ...
Highlighting ZIOPHARM Oncology Inc. (ZIOP) As A Catalyst Play This Quarter
In Donald Trump’s latest press conference, the President-elect took a swipe at the healthcare and pharmaceutical space, suggesting that drug companies are getting away with ...
Biotech Movers: Illumina, Inc. (ILMN) And EnteroMedics Inc (ETRM)
The JP Morgan conference took place in the biotech sector this week, and as such, we have seen an incredible amount of volatility spread across the space.
Pluristem Therapeutics Inc. (PSTI) To Begin CLI Phase III Trial Enrolling Only 250 Patients, With FDA Blessing
If we could point to one thing that keeps Big Pharma on top and smaller pharmaceutical companies dependent, it’s the exorbitant costs of phase III trials.
Johnson & Johnson (JNJ) Gets $17 Million From NYC For JLABS Incubator
Johnson & Johnson (NYSE:JNJ) is embarking on a new project. New York Gov.
Alinity ci-series Of Diagnostic Systems From Abbott Laboratories (ABT) Obtains CE Mark
Alinity, a family of next-generation clinical chemistry and immunoassay diagnostics from Abbott Laboratories (NYSE:ABT) is now being offered in Europe and other countries that...
Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen
Sarepta Therapeutics Inc (NASDAQ:SRPT) is one of the week’s biggest winners from the J.P.
Vistagen Therapeutics Inc (VTGN) Finds Stem Cell Partner In Bayer AG (ADR) (BAYRY) With Phase II TRD Data On Tap
We last covered Vistagen Therapeutics Inc (NASDAQ:VTGN) back in September, focusing primarily on its flagship AV-101 for treatment-resistant depression (TRD).
Emergent Technologies’ Pure MHC Explores A New Collaboration With AbbVie Inc (ABBV)
AbbVie Inc (NYSE:ABBV) has sought a joint venture with its target discovery portfolio company, Emergent Technologies Inc, Pure MHC.
Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has resolved to dispose of its cancer drugs unit to Ipsen. Some of these drugs include Doxil and Onivyde.
AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) and Palatin Technologies, Inc.
Pfizer Inc. (PFE) Challenges Businessmen To Come Up With Breast Cancer Solutions
Pfizer Inc. (NYSE:PFE) is stepping up its battle against breast cancer.
Egalet Corp (EGLT) Gets Approval But Fails On Labelling, Here’s What’s Next
Corrections: Insider Monkey was contacted by Egalet regarding some of the facts that appeared in the below article.
Biotech Movers: EnteroMedics Inc (ETRM) And Stemline Therapeutics Inc (STML)
We’re off to a big start for the fresh week in the biotech space, as the lull in volume that generally comes on the back of the holiday period has subsided, and both the institutional...
Adamas Pharmaceuticals Inc (ADMS) Is Up On PDUFA: What’s Next?
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is up close to 15% on its 2017 open, on the back of a couple of positive developments out of its Parkinson’s disease pipeline.
